Pharsight

Ciprodex generic

Ciprodex is an otic drug owned by Novartis. It contains the active ingredients Ciprofloxacin and Dexamethasone. Ciprodex was first authorized for market use on 18th July 2003.

When will Ciprodex generic be available?

The generic versions of Ciprodex are expected to be available post 4th June 2025. This is due to the expiry of the last patent (US8846650) held for this drug, which is titled 'Method of treating middle ear infections'.

Ciprodex uses

Ciprodex, in suspension/drops form, is used for the treatment of acute otitis media and acute otitis externa. The active ingredients - Ciprofloxacin, a bacterial antibiotic, and Dexamethasone, a corticosteroid, work together in treating these ear infections by stopping the growth of bacteria and reducing ear swelling and discomfort.

Ciprodex patent expiration

Ciprodex currently holds one active patent titled 'Method of treating middle ear infections', which expires on 4th June 2025. The other three patents have already expired. Check below the patent table for the details. Although the manufacturing company, Novartis, may have other patents for Ciprodex, the release date of the Ciprodex generic version is largely dependent on the last active patent - US8846650 - expiry date.

EPO Oppostions filed on Ciprodex

Ciprodex dosage

Want to ask something?